



Clinical trial results:

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Summary

EudraCT number	2019-003304-12
Trial protocol	DE GB
Global end of trial date	26 July 2022

Results information

Result version number	v1 (current)
This version publication date	04 October 2023
First version publication date	04 October 2023

Trial information

Trial identification

Sponsor protocol code	D9182C00001
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04212169
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AstraZeneca
Sponsor organisation address	1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Public contact	Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com
Scientific contact	Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 November 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 February 2022
Global end of trial reached?	Yes
Global end of trial date	26 July 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD.

Protection of trial subjects:

The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and applicable regulatory requirements. All participant must meet all inclusion criteria and not meet any exclusion criteria before receiving investigational product. IDMC was formed to monitor potential risk in the study.

Background therapy:

Participants who meet the eligibility (inclusion/exclusion) criteria will discontinue use of topical corticosteroids and topical calcineurin inhibitorss at Visit 2. Subjects will be required to apply moisturizers twice daily for at least 7 days before randomization at Visit 3 (Day 1) with a minimum of 85% compliance

Evidence for comparator:

Not applicable as there was no comparator arm in the study

Actual start date of recruitment	09 December 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 2
Country: Number of subjects enrolled	Germany: 11
Country: Number of subjects enrolled	Poland: 16
Country: Number of subjects enrolled	Spain: 12
Country: Number of subjects enrolled	United Kingdom: 91
Country: Number of subjects enrolled	United States: 16
Worldwide total number of subjects	148
EEA total number of subjects	39

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	148
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 6 countries between 19 Dec 2019 and 20 Sep 2022. A total of 329 participants were screened in the study.

Pre-assignment

Screening details:

Out of 329 participants, 148 were randomised and treated in the study with 3:1:1:3 overall ratio to receive either placebo (56 subjects), MEDI3506 dose 1 (19 subjects), MEDI3506 dose 2 (18 subjects), or MEDI3506 dose 3 (55 subjects).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

Blinding implementation details:

Subject was randomised using an interactive web response system to receive either of 3 doses of MEDI3506 or placebo. Participants, investigators and the sponsors are blinded with regard to the actual dose information.

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Pooled Placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85

Arm title	MEDI3506 Dose 1
------------------	-----------------

Arm description:

MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks

Arm type	Experimental
Investigational medicinal product name	MEDI3506 Dose 1
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85.

Arm title	MEDI3506 Dose 2
------------------	-----------------

Arm description:

MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks

Arm type	Experimental
----------	--------------

Investigational medicinal product name	MEDI3506 Dose 2
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
Given subcutaneously on Day 1, Day 29, Day 57 and Day 85	
Arm title	MEDI3506 Dose 3

Arm description:

MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks

Arm type	Experimental
Investigational medicinal product name	MEDI3506 Dose 3
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85

Number of subjects in period 1	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2
Started	56	19	18
Completed	42	16	13
Not completed	14	3	5
Consent withdrawn by subject	10	2	5
Adverse event, non-fatal	-	-	-
Lost to follow-up	1	-	-
Other reason, unspecified	3	1	-

Number of subjects in period 1	MEDI3506 Dose 3
Started	55
Completed	42
Not completed	13
Consent withdrawn by subject	7
Adverse event, non-fatal	2
Lost to follow-up	2
Other reason, unspecified	2

Baseline characteristics

Reporting groups

Reporting group title	Placebo
Reporting group description:	
Pooled Placebo	
Reporting group title	MEDI3506 Dose 1
Reporting group description:	
MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks	
Reporting group title	MEDI3506 Dose 2
Reporting group description:	
MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks	
Reporting group title	MEDI3506 Dose 3
Reporting group description:	
MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks	

Reporting group values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2
Number of subjects	56	19	18
Age categorical			
Units: Subjects			
Adults (18-35 years)	39	16	9
From 36-75 years	17	3	9
Age Continuous			
Units: Years			
arithmetic mean	32.3	28.7	37.9
standard deviation	± 11.4	± 8.9	± 14.3
Sex: Female, Male			
Units: Participants			
Female	27	8	7
Male	29	11	11
Race (NIH/OMB)			
Units: Subjects			
AMERICAN INDIAN OR ALASKA NATIVE	0	0	0
ASIAN	8	5	3
BLACK OR AFRICAN AMERICAN	1	1	2
MULTIPLE CATEGORIES CHECKED	1	0	1
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	0
OTHER	0	0	1
WHITE	46	13	11
Region of Enrollment			
Units: Subjects			
USA	6	0	3
Australia	0	0	1
Germany	5	1	3
Spain	7	0	0
United Kingdom	34	13	9
Poland	4	5	2

Eczema Area and Severity Index (EASI) score			
Eczema Area and Severity Index (EASI) score is a composite score of area of involvement and severity score of 4 different body areas. The severity score is based on erythema, oedema/papulation, excoriation and lichenification of 4 body areas which are head, trunk, upper limbs and lower limbs. The score ranges between 0 to 72 points. Higher EASI score indicates more severe disease.			
Units: Scores on a scale			
arithmetic mean	28.81	28.94	28.36
standard deviation	± 8.9	± 11.66	± 11.87

Reporting group values	MEDI3506 Dose 3	Total	
Number of subjects	55	148	
Age categorical			
Units: Subjects			
Adults (18-35 years)	32	96	
From 36-75 years	23	52	
Age Continuous			
Units: Years			
arithmetic mean	34.6	-	
standard deviation	± 11.8	-	
Sex: Female, Male			
Units: Participants			
Female	25	67	
Male	30	81	
Race (NIH/OMB)			
Units: Subjects			
AMERICAN INDIAN OR ALASKA NATIVE	0	0	
ASIAN	6	22	
BLACK OR AFRICAN AMERICAN	2	6	
MULTIPLE CATEGORIES CHECKED	0	2	
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER	0	0	
OTHER	2	3	
WHITE	45	115	
Region of Enrollment			
Units: Subjects			
USA	7	16	
Australia	1	2	
Germany	2	11	
Spain	5	12	
United Kingdom	35	91	
Poland	5	16	
Eczema Area and Severity Index (EASI) score			
Eczema Area and Severity Index (EASI) score is a composite score of area of involvement and severity score of 4 different body areas. The severity score is based on erythema, oedema/papulation, excoriation and lichenification of 4 body areas which are head, trunk, upper limbs and lower limbs. The score ranges between 0 to 72 points. Higher EASI score indicates more severe disease.			
Units: Scores on a scale			
arithmetic mean	32.3	-	
standard deviation	± 10.86	-	

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description: Pooled Placebo	
Reporting group title	MEDI3506 Dose 1
Reporting group description: MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks	
Reporting group title	MEDI3506 Dose 2
Reporting group description: MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks	
Reporting group title	MEDI3506 Dose 3
Reporting group description: MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks	

Primary: Percent Change from Baseline to Week 16 in EASI score

End point title	Percent Change from Baseline to Week 16 in EASI score
End point description: The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.	
End point type	Primary
End point timeframe: Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	55	19	17	54
Units: Percentage of change from baseline				
least squares mean (standard error)				
Repeated measures mixed model	-51.31 (± 5.214)	-50.03 (± 7.419)	-45.43 (± 8.402)	-53.02 (± 4.858)
MCP-mod dose response model	0 (± 0)	0 (± 0)	0 (± 0)	0 (± 0)

Statistical analyses

Statistical analysis title	Difference in % change in EASI score
Comparison groups	MEDI3506 Dose 1 v Placebo

Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.888
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	1.27
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.67
upper limit	16.22
Variability estimate	Standard error of the mean
Dispersion value	8.981

Statistical analysis title	Difference in % change in EASI score
Comparison groups	MEDI3506 Dose 3 v Placebo
Number of subjects included in analysis	109
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.807
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-1.72
Confidence interval	
level	90 %
sides	2-sided
lower limit	-13.38
upper limit	9.95
Variability estimate	Standard error of the mean
Dispersion value	7.014

Statistical analysis title	Difference in % change in EASI score
Comparison groups	MEDI3506 Dose 2 v Placebo
Number of subjects included in analysis	72
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.549
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	5.87
Confidence interval	
level	90 %
sides	2-sided
lower limit	-10.36
upper limit	22.1

Variability estimate	Standard error of the mean
Dispersion value	9.756

Secondary: Percentage of Subjects achieving a 90% reduction from baseline in EASI Score at week 16

End point title	Percentage of Subjects achieving a 90% reduction from baseline in EASI Score at week 16
-----------------	---

End point description:

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
Number of participants achieving reduction	0	0	1	3

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects achieving a 75% reduction from baseline in EASI Score at week 16

End point title	Percentage of Subjects achieving a 75% reduction from baseline in EASI Score at week 16
-----------------	---

End point description:

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
Number of participants achieving reduction	4	2	1	10

Statistical analyses

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 1 v Placebo
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6396
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	1.53
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.19
upper limit	9.94

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 3 v Placebo
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0935
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	2.89
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.91
upper limit	10.49

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 2 v Placebo

Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.9999
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	0.76
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.03
upper limit	6.38

Secondary: Percentage of Subjects achieving a 50% reduction from baseline in EASI Score at week 16

End point title	Percentage of Subjects achieving a 50% reduction from baseline in EASI Score at week 16
End point description: To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score.	
End point type	Secondary
End point timeframe: Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
Number of participants achieving reduction	12	5	5	16

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects achieving an IGA of 0 (clear) or 1 (almost clear) with at least a 2 grade reduction from baseline score at Week 16

End point title	Percentage of subjects achieving an IGA of 0 (clear) or 1 (almost clear) with at least a 2 grade reduction from baseline score at Week 16
End point description: The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease).	
End point type	Secondary

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
IGA response	1	1	0	5
IGA response using MCP-Mod dose-response analysis	0	0	0	0

Statistical analyses

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 1 v Placebo
Number of subjects included in analysis	75
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.445
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	3.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.08
upper limit	119.65

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 3 v Placebo
Number of subjects included in analysis	111
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1132
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	5.5
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.75
upper limit	130.35

Statistical analysis title	Odds ratio
Comparison groups	MEDI3506 Dose 2 v Placebo
Number of subjects included in analysis	74
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9999
Method	Fisher exact
Parameter estimate	Odds ratio (OR)
Point estimate	0
Confidence interval	
level	90 %
sides	2-sided
lower limit	0
upper limit	28

Secondary: Percentage of subjects achieving a reduction of ≥ 3 from baseline to Week 16 in weekly mean of daily peak pruritus NRS

End point title	Percentage of subjects achieving a reduction of ≥ 3 from baseline to Week 16 in weekly mean of daily peak pruritus NRS
End point description:	Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.
End point type	Secondary
End point timeframe:	
Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants	9	3	3	12

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in weekly mean of daily peak pruritus NRS

End point title	Change from baseline to Week 16 in weekly mean of daily peak pruritus NRS
-----------------	---

End point description:

Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	28	14	10	29
Units: Scores on a scale				
arithmetic mean (standard deviation)	-1.98 (± 2.38)	-1.18 (± 2.72)	-2.12 (± 1.61)	-2.49 (± 2.01)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in weekly mean of daily peak skin pain NRS

End point title	Change from baseline to Week 16 in weekly mean of daily peak skin pain NRS
-----------------	--

End point description:

Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	41	16	12	40
Units: Scores on a scale				
arithmetic mean (standard deviation)	-1.44 (± 2.39)	-1.66 (± 2.62)	-1.52 (± 1.61)	-1.63 (± 2.30)

Statistical analyses

No statistical analyses for this end point

Secondary: SCORAD: Percent change from baseline to Week 16

End point title	SCORAD: Percent change from baseline to Week 16
End point description: SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease.	
End point type	Secondary
End point timeframe: Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	15	12	40
Units: Percentage of change from baseline				
arithmetic mean (standard deviation)	-31.79 (± 25.09)	-29.88 (± 23.14)	-36.22 (± 25.34)	-39.42 (± 25.44)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in percentage body surface area (BSA) affected by AD

End point title	Change from baseline to Week 16 in percentage body surface area (BSA) affected by AD
End point description: Change in percentage of body surface area (BSA) affected by AD from baseline at week 16.	
End point type	Secondary
End point timeframe: Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	37	15	13	40
Units: Percentage of body surface area				
arithmetic mean (standard deviation)	-17.81 (± 17.09)	-11.07 (± 10.92)	-9.46 (± 13.23)	-23.13 (± 19.35)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in DLQI

End point title	Change from baseline to Week 16 in DLQI
-----------------	---

End point description:

The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all /not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	15	12	40
Units: Scores on scale				
arithmetic mean (standard deviation)	-2.9 (± 5.3)	-2.1 (± 6.5)	-2.4 (± 4.9)	-2.7 (± 4.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Patient description of Atopic Dermatitis or eczema from Patient Global Impression of Severity at Week 16

End point title	Patient description of Atopic Dermatitis or eczema from Patient Global Impression of Severity at Week 16
-----------------	--

End point description:

The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
No symptoms No in category at week 16	1	0	1	1
Very mild No in category at week 16	5	0	5	10
Mild No in category at week 16	9	4	2	8
Moderate No in category at week 16	11	5	1	14
Severe No in category at week 16	11	4	2	6

Very severe No in category at week 16	1	2	1	1
Missing data No in category at week 16	18	4	6	15

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in POEM

End point title	Change from baseline to Week 16 in POEM
End point description:	
The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease	
End point type	Secondary
End point timeframe:	
Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	15	12	40
Units: Scores on scale				
arithmetic mean (standard deviation)	-5.4 (± 7.9)	-2.5 (± 4.8)	-3.7 (± 8.7)	-6.3 (± 6.9)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in 5-D itch

End point title	Change from baseline to Week 16 in 5-D itch
End point description:	
The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome	
End point type	Secondary
End point timeframe:	
Week 16	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	15	12	40
Units: Scores on scale				
arithmetic mean (standard deviation)	-3.0 (± 4.9)	-3.0 (± 2.6)	-3.8 (± 3.4)	-4.0 (± 5.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Occurrence of Adverse Events

End point title	Occurrence of Adverse Events
End point description: To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe: up to 24 weeks	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participant				
At least one adverse event	37	9	14	32
At least one investigational product related event	7	3	7	8
At least one event of ≥ grade 3 severity	7	2	2	5
At least one serious event	2	0	2	1
At least one IP related serious event	0	0	1	0

Statistical analyses

No statistical analyses for this end point

Secondary: Oral or tympanic temperature taken during vital signs assessment

End point title	Oral or tympanic temperature taken during vital signs assessment
End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe: Baseline, week 16 and week 24	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: degrees C				
arithmetic mean (standard deviation)				
Baseline	36.46 (± 0.35)	36.43 (± 0.52)	36.41 (± 0.43)	36.52 (± 0.39)
Week 16	36.49 (± 0.36)	36.71 (± 0.41)	36.50 (± 0.32)	36.47 (± 0.39)
Week 24	36.44 (± 0.43)	36.63 (± 0.50)	36.55 (± 0.42)	36.51 (± 0.37)

Statistical analyses

No statistical analyses for this end point

Secondary: Systolic blood pressure taken during vital signs assessment

End point title	Systolic blood pressure taken during vital signs assessment
End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe: Baseline, week 16 and week 24	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: mmHg				
arithmetic mean (standard deviation)				
Baseline	117.7 (± 12.9)	119.3 (± 9.2)	123.8 (± 9.9)	121.5 (± 12.5)
Week 16	117.8 (± 9.6)	117.3 (± 7.2)	120.7 (± 13.6)	119.8 (± 10.6)
Week 24	118.9 (± 11.1)	117.6 (± 11.4)	120.1 (± 15.1)	120.6 (± 12.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Heart rate taken during vital signs assessment

End point title	Heart rate taken during vital signs assessment
End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506	

compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
End point timeframe:	
Baseline, week 16 and week 24	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Pulse Rate (beats/min)				
arithmetic mean (standard deviation)				
Baseline	68.1 (± 9.8)	66.6 (± 8.7)	71.3 (± 9.3)	68.2 (± 11.1)
Week 16	69.4 (± 10.1)	66.9 (± 10.6)	65.9 (± 8.6)	66.4 (± 11.0)
Week 24	72.0 (± 13.5)	67.0 (± 10.4)	74.1 (± 8.7)	67.6 (± 10.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Respiratory rate collected during vital signs assessment

End point title	Respiratory rate collected during vital signs assessment
End point description:	
Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe:	
Baseline, week 16 and week 24	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: breaths/min				
arithmetic mean (standard deviation)				
Baseline	15.4 (± 2.2)	16.0 (± 1.5)	16.2 (± 1.8)	15.5 (± 1.8)
Week 16	16.0 (± 2.3)	15.7 (± 1.8)	16.3 (± 1.9)	15.9 (± 1.4)
Week 24	15.8 (± 2.4)	16.1 (± 1.5)	17.1 (± 2.4)	15.6 (± 1.6)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology

End point title	Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology
End point description: To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe: up to 24 weeks	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
Basophil AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Eosinophil AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Hematocrit AtLeastOne PostBaseline Value BelowLLN	4	3	2	7
Hb AtLeastOne PostBaseline Value BelowLLN	5	1	3	8
Lymphocyte AtLeastOne PostBaseline Value BelowLLN	6	0	3	10
Monocyte AtLeastOne PostBaseline Value BelowLLN	1	0	1	3
Platelet AtLeastOne PostBaseline Value BelowLLN	1	1	0	0
Erythrocyte AtLeastOne PostBaseline Value BelowLLN	10	3	4	17
WCC AtLeastOne PostBaseline Value BelowLLN	7	1	2	6
Basophil AtLeastOne PostBaseline Value AboveULN	3	0	0	0
Eosinophil AtLeastOne PostBaseline Value AboveULN	22	4	5	14
Hematocrit AtLeastOne PostBaseline Value AboveULN	0	0	1	0
Hb AtLeastOne PostBaseline Value AboveULN	0	0	1	0
Lymphocyte AtLeastOne PostBaseline Value AboveULN	0	0	0	0
Monocyte AtLeastOne PostBaseline Value AboveULN	2	0	2	3
Platelet AtLeastOne PostBaseline Value AboveULN	3	0	2	5
Erythrocyte AtLeastOne PostBaseline Value AboveULN	0	0	0	0
WCCT AtLeastOne PostBaseline Value AboveULN	5	2	0	2
Basophil Values within normal range	53	19	18	55
Eosinophil Values within normal range	34	15	13	41
Hematocrit Values within normal range	52	16	15	48
Hb Values within normal range	51	18	14	47

Lymphocyte Values within normal range	50	19	15	45
Monocyte Values within normal range	53	19	15	49
Platelet Values within normal range	52	18	16	50
Erythrocyte Values within normal range	46	16	14	38
WCC Values within normal range	44	16	16	47

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry

End point title	Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry
-----------------	---

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

up to 24 weeks

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
Albumin AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
ALP AtLeastOne PostBaseline Value BelowLLN	3	0	0	2
ALT AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
AST AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Bilirubin AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Urea AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Creatinine AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
GGT AtLeastOne PostBaseline Value BelowLLN	4	2	0	5
Potassium AtLeastOne PostBaseline Value BelowLLN	1	1	0	1
Sodium A LeastOne PostBaseline Value BelowLLN	0	0	0	0
Albumin AtLeastOne PostBaseline Value AboveULN	21	5	6	15
ALP AtLeastOne PostBaseline Value AboveULN	3	2	2	4
ALT AtLeastOne PostBaseline Value AboveULN	7	4	4	5

AST AtLeastOne PostBaseline Value AboveULN	6	3	3	8
Bilirubin AtLeastOne PostBaseline Value AboveULN	3	0	1	1
Urea AtLeastOne PostBaseline Value AboveULN	0	0	0	2
Creatinine AtLeastOne PostBaseline Value AboveULN	0	0	1	3
GGT AtLeastOne PostBaseline Value AboveULN	2	3	2	1
Potassium AtLeastOne PostBaseline Value AboveULN	1	0	1	1
Sodium AtLeastOne PostBaseline Value AboveULN	2	0	0	2
Albumin Values within normal range	35	14	12	40
ALP Values within normal range	50	17	16	49
ALT Values within normal range	49	15	14	50
AST Values within normal range	50	16	15	47
Bilirubin Values within normal range	53	19	17	54
Urea Values within normal range	56	19	18	53
Creatinine Values within normal range	56	19	17	52
GGT Values within normal range	50	14	16	49
Potassium Values within normal range	54	18	17	53
Sodium Values within normal range	54	19	18	53

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis

End point title	Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis
-----------------	--

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

up to 24 weeks

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: Participants				
pH AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Erythrocyte AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
Sp gravity AtLeastOne PostBaseline Value BelowLLN	0	0	0	0

Leukocyte AtLeastOne PostBaseline Value BelowLLN	0	0	0	0
pH AtLeastOne PostBaseline Value AboveULN	0	0	0	1
Erythrocyte AtLeastOne PostBaseline Value AboveULN	8	2	1	6
Sp gravity AtLeastOne PostBaseline Value AboveULN	4	0	3	7
Leukocyte AtLeas One PostBaseline Value AboveULN	4	2	1	5
pH Values within normal range	56	19	18	54
Erythrocyte Values within normal range	48	17	17	49
Sp gravity Values within normal range	52	19	15	48
Leukocyte Values within normal range	52	17	17	50

Statistical analyses

No statistical analyses for this end point

Secondary: Heart rate (beats/min) recorded on ECGs

End point title	Heart rate (beats/min) recorded on ECGs
End point description:	
Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.	
End point type	Secondary
End point timeframe:	
Baseline, week 16 and week 24	

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: beats per minute				
arithmetic mean (standard deviation)				
Baseline	67.59 (± 9.82)	65.61 (± 6.87)	72.63 (± 9.82)	65.18 (± 9.43)
Week 16	66.02 (± 9.97)	63.80 (± 8.56)	65.42 (± 9.08)	63.05 (± 10.61)
Week 24	68.17 (± 13.94)	63.88 (± 10.41)	72.46 (± 9.12)	64.58 (± 9.43)

Statistical analyses

No statistical analyses for this end point

Secondary: QT (milliseconds) recorded on ECGs

End point title	QT (milliseconds) recorded on ECGs
-----------------	------------------------------------

End point description:

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, week 16 and week 24

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: milliseconds				
arithmetic mean (standard deviation)				
Baseline	385.43 (± 27.75)	390.67 (± 20.57)	380.04 (± 26.38)	390.27 (± 22.69)
Week 16	387.05 (± 26.14)	390.40 (± 24.24)	395.75 (± 20.36)	391.95 (± 29.22)
Week 24	385.88 (± 34.31)	398.69 (± 28.52)	383.15 (± 19.05)	393.40 (± 26.54)

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Investigator's overall ECGs evaluations, e.g. normal/abnormal and their clinical significance

End point title	Number of Participants with Investigator's overall ECGs evaluations, e.g. normal/abnormal and their clinical significance
-----------------	---

End point description:

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16 and week 24

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: participants				
Week 16 Abnormal ECG: Clinically significant	0	0	0	0
Week 24 Abnormal ECG: Clinically significant	0	0	0	0
Week 16 Abnormal ECG: Not Clinically significant	3	2	2	10

Week 24 Abnormal ECG: Not Clinically significant	4	4	2	11
Week 16 Normal ECG	38	13	10	32
Week 24 Normal ECG	38	12	11	29
Week 16 Missing	15	4	6	13
Week 24 Missing	14	3	5	15

Statistical analyses

No statistical analyses for this end point

Secondary: Left Ventricular Ejection Fraction measured by Echocardiogram

End point title	Left Ventricular Ejection Fraction measured by Echocardiogram
-----------------	---

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline and week 16

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: % LVEF				
arithmetic mean (standard deviation)				
Baseline	64.3 (± 6.3)	64.7 (± 6.2)	62.8 (± 5.2)	63.6 (± 4.7)
Week 16	64.3 (± 5.9)	63.0 (± 4.4)	61.0 (± 3.6)	65.2 (± 5.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Serum MEDI3506 concentration profiles

End point title	Serum MEDI3506 concentration profiles ^[1]
-----------------	--

End point description:

To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16 and week 24

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Placebo arm not included since this is PK

End point values	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	18	17	48	
Units: µg/mL				
geometric mean (geometric coefficient of variation)				
Week 16	0.377 (± 242)	2.158 (± 193)	5.979 (± 118)	
Week 24	0.018 (± 184)	0.118 (± 298)	0.188 (± 234)	

Statistical analyses

No statistical analyses for this end point

Secondary: Occurrence of Anti-drug antibody during the treatment and follow-up periods

End point title	Occurrence of Anti-drug antibody during the treatment and follow-up periods
End point description:	To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD.
End point type	Secondary
End point timeframe:	up to 24 weeks

End point values	Placebo	MEDI3506 Dose 1	MEDI3506 Dose 2	MEDI3506 Dose 3
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	19	18	55
Units: participants				
Number of ADA positive participants at baseline	1	0	0	0
Number of ADA positive participants post baseline	1	1	0	2

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

24 weeks

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.0
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Pooled Placebo

Reporting group title	MEDI3506 Dose 3
-----------------------	-----------------

Reporting group description:

MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks

Reporting group title	MEDI3506 Dose 2
-----------------------	-----------------

Reporting group description:

MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks

Reporting group title	MEDI3506 Dose 1
-----------------------	-----------------

Reporting group description:

MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks

Serious adverse events	Placebo	MEDI3506 Dose 3	MEDI3506 Dose 2
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 56 (3.57%)	1 / 55 (1.82%)	2 / 18 (11.11%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Vascular disorders			
Venous thrombosis limb			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Medical device removal			
subjects affected / exposed	0 / 56 (0.00%)	1 / 55 (1.82%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food allergy			

subjects affected / exposed	1 / 56 (1.79%)	0 / 55 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Dermatitis exfoliative generalised			
subjects affected / exposed	1 / 56 (1.79%)	0 / 55 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Covid-19 pneumonia			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	MEDI3506 Dose 1		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 19 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Vascular disorders			
Venous thrombosis limb			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Medical device removal			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Food allergy			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Dermatitis exfoliative generalised			

subjects affected / exposed	0 / 19 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Covid-19 pneumonia			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo	MEDI3506 Dose 3	MEDI3506 Dose 2
Total subjects affected by non-serious adverse events			
subjects affected / exposed	29 / 56 (51.79%)	25 / 55 (45.45%)	14 / 18 (77.78%)
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Injection site swelling			
subjects affected / exposed	1 / 56 (1.79%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Injection site reaction			
subjects affected / exposed	0 / 56 (0.00%)	4 / 55 (7.27%)	1 / 18 (5.56%)
occurrences (all)	0	6	1
Injection site bruising			
subjects affected / exposed	0 / 56 (0.00%)	1 / 55 (1.82%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Influenza like illness			
subjects affected / exposed	1 / 56 (1.79%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Dyspnoea subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Investigations Liver function test increased subjects affected / exposed occurrences (all) Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) Urine analysis abnormal subjects affected / exposed occurrences (all)	2 / 56 (3.57%) 2 0 / 56 (0.00%) 0 1 / 56 (1.79%) 1	0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0	0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0
Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Fall subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0 1 / 56 (1.79%) 1	0 / 55 (0.00%) 0 0 / 55 (0.00%) 0	1 / 18 (5.56%) 1 1 / 18 (5.56%) 1
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Nervous system disorders Presyncope subjects affected / exposed occurrences (all) Carpal tunnel syndrome subjects affected / exposed occurrences (all) Headache	0 / 56 (0.00%) 0 0 / 56 (0.00%) 0	0 / 55 (0.00%) 0 0 / 55 (0.00%) 0	0 / 18 (0.00%) 0 0 / 18 (0.00%) 0

subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 55 (0.00%) 0	0 / 18 (0.00%) 0
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	3 / 56 (5.36%) 3	0 / 55 (0.00%) 0	0 / 18 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all) Aphthous ulcer subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Dry mouth subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0	0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 1 / 55 (1.82%) 1 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 1 / 55 (1.82%) 1	1 / 18 (5.56%) 1 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 1 / 18 (5.56%) 2 1 / 18 (5.56%) 1
Skin and subcutaneous tissue disorders Dermatitis atopic subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all)	12 / 56 (21.43%) 14 3 / 56 (5.36%) 3 3 / 56 (5.36%) 3	14 / 55 (25.45%) 17 1 / 55 (1.82%) 1 2 / 55 (3.64%) 3	0 / 18 (0.00%) 0 2 / 18 (11.11%) 2 2 / 18 (11.11%) 2
Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1

Pain in extremity subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0	2 / 18 (11.11%) 3
Infections and infestations			
Cellulitis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 2
Bronchitis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Acarodermatitis subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	0 / 18 (0.00%) 0
Conjunctivitis subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	1 / 55 (1.82%) 1	1 / 18 (5.56%) 1
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1	1 / 18 (5.56%) 1
Otitis externa subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1	1 / 18 (5.56%) 1
Oral herpes subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 2
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 56 (1.79%) 1	3 / 55 (5.45%) 3	2 / 18 (11.11%) 2
Influenza subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0	1 / 18 (5.56%) 1
Eczema infected			

subjects affected / exposed	1 / 56 (1.79%)	0 / 55 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Dermatitis infected			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 56 (0.00%)	0 / 55 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Covid-19			
subjects affected / exposed	7 / 56 (12.50%)	2 / 55 (3.64%)	0 / 18 (0.00%)
occurrences (all)	7	2	0

Non-serious adverse events	MEDI3506 Dose 1		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 19 (57.89%)		
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 19 (5.26%)		
occurrences (all)	1		
General disorders and administration site conditions			
Injection site swelling			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		
Injection site bruising			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		
Influenza like illness			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Oropharyngeal pain			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		

Dyspnoea subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Investigations Liver function test increased subjects affected / exposed occurrences (all) Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) Urine analysis abnormal subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1		
Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Fall subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0 0 / 19 (0.00%) 0		
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Nervous system disorders Presyncope subjects affected / exposed occurrences (all) Carpal tunnel syndrome subjects affected / exposed occurrences (all) Headache	1 / 19 (5.26%) 1 1 / 19 (5.26%) 1		

subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1		
Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all) Aphthous ulcer subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Dry mouth subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0		
Skin and subcutaneous tissue disorders Dermatitis atopic subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all)	2 / 19 (10.53%) 2 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0		
Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		

Pain in extremity subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Infections and infestations			
Cellulitis subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Bronchitis subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Acarodermatitis subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1		
Conjunctivitis subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Otitis externa subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Oral herpes subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1		
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 19 (5.26%) 1		
Influenza subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 19 (0.00%) 0		
Eczema infected			

subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		
Dermatitis infected			
subjects affected / exposed	1 / 19 (5.26%)		
occurrences (all)	1		
Folliculitis			
subjects affected / exposed	1 / 19 (5.26%)		
occurrences (all)	1		
Covid-19			
subjects affected / exposed	0 / 19 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
01 October 2019	Amendment 1
24 October 2019	Amendment 2
13 January 2020	Amendment 3
27 March 2020	Amendment 4
03 June 2020	Amendment 5
07 September 2020	Amendment 6
29 October 2020	Amendment 7
23 February 2021	Amendment 8
15 June 2022	Amendment 9

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
26 March 2020	Subject recruitment was temporarily placed on hold on 26 March 2020 due to COVID-19 pandemic. Subject recruitment was restarted on a site-by-site basis after gaining regulatory and ethical approval of Protocol Amendment 5 and reviewing the local epidemiological situation and the ability of each site to safely conduct the study in the new circumstances	03 June 2020

Notes:

Limitations and caveats

None reported